Diabetes

By Heather Mack April 18, 2017
There’s been a lot of talk about sweat-centric technology, with hopeful researchers and digital health entrepreneurs citing the potential for wearables that measure the salty substance to offer up a bevy of biometric insights ranging from athletic performance to glucose monitoring. But the latest scientific undertaking suggests sweat-sensing wearables could go much further: diagnosing disease. In...
By Jonah Comstock April 13, 2017
Apple has even more secret health aspirations than anyone realized, according to reporting by Christina Farr for CNBC yesterday. Citing sources inside the company, Farr reports that Apple has a small offsite team dedicated to diabetes research that's been working for about five years. The goal is one many other tech companies are working on but no one's close to cracking: noninvasive, continuous...
By Tom Sullivan April 11, 2017
Amazon Web Services and Merck announced a developer competition on Monday to that plans to harness artificial intelligence for diabetics. Dubbed the Alexa Diabetes Challenge, and powered by Luminary Labs, the contest aims to incent upstarts and individual developers to create apps that harness Amazon’s Alexa voice-enabled technologies particularly for patients recently diagnosed with Type 2...
By Jonah Comstock April 6, 2017
Following in the footsteps of Eli Lilly and Roche, Sanofi has quietly received FDA clearance for a smartphone app with a built-in insulin dose calculator. According to FDA documents, the app, cleared at the end of March, is called My Dose Coach. A pending trademark application gives a more in-depth description of the app, describing it as "downloadable software in the nature of a mobile...
By Jonah Comstock March 28, 2017
Despite all the convenience features of modern smartwatches, for users it’s still all about fitness, according to recently released data from Parks Associates.  The research firm says that tracking steps is the most popular smartwatch use case, with 60 percent of the United States’ 13.3 million smartwatch users reporting that they track their steps with their device. According to Senior Director...
By Jonah Comstock March 3, 2017
Implantable longterm continuous glucose monitor company Senseonics is in a better place than its financials would suggest. The company posted a net loss of $9.9 million last quarter, up from an $8.4 million loss in the year prior, and is planning to borrow about $5 million from the Oxford Silicon Valley Bank that it’s already $20 million in debt to. But Senseonic’s potentially game-changing...
By Jonah Comstock February 12, 2017
More than two years ago, when Apple first added a list of diabetes management apps to its app store, we covered the list of 13 top picks. A lot can change in a few years, however. And while a few of those same apps still appear on Apple’s current list of 12 diabetes management apps, there’s plenty of new names — though not all new to MobiHealthNews readers — as well. Read on for Apple’s current...
By Jonah Comstock January 19, 2017
Updated with statement from Eli Lilly Indianapolis-based pharma company Eli Lilly recently recieved FDA 510K clearance for a new mobile app called Go Dose, a diabetes management and insulin dosing app for users of Humalog, Lilly's rapid-acting insulin. The clearance is for prescription use, but includes two versions of the app: Go Dose, for patients, and Go Dose Pro, for healthcare providers. "...
By Heather Mack January 5, 2017
Diabetes management device maker Intuity Medical has raised another $15 million in Series C funding in a round led by PTV Healthcare Capital, new investors KCK Group, and affiliates of Luther King Capital Management. Existing investors Accuitive Medical Ventures, Investor Growth Capital, US Venture Partners, Venrock and Versant Ventures also contributed to the round. The company, which makes an...
By Heather Mack December 2, 2016
Germantown, Maryland-based Senseonics, which is working on a long-term implantable continuous glucose monitor called Eversense, has expanded its exclusive distribution agreement with Roche. Now, Roche will have exclusive rights to promote, market and sell the Eversense product line to diabetes clinics and patients in in most of Europe (excluding Scandinavia and Finland), the Middle East (except...